Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700
Expand allThis document outlines details of PBS-subsidised brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma (HL) and who have failed autologous stem cell transplant (ASCT) or are ASCT naïve.
HL and listing dates
HL is a cancer of the immune system.
Listing dates:
- brentuximab vedotin- 1 April 2017
- pembrolizumab - 1 May 2018
See Written Authority Required Drugs for more information.
Enquiries
Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.
The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.
Related links
Tier 0 technical support - self-sufficiency
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Written Authority Required Drugs